All In Biotech

NDA 020639 · Cheplapharm

Seroquel

Quetiapine Fumarate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Sep 26, 1997

Approved uses

8

Original approval plus efficacy supplements

Registered trials

398

129 Phase 3, 13 recruiting

FAERS reports

157,490

125,741 serious, 22,048 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1) ] . SEROQUEL is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.2) ]. In...

What it is approved for

From the label in effect Apr 10, 2026.

SEROQUEL is an atypical antipsychotic indicated for the treatment of: • Schizophrenia ( 1.1 ) • Bipolar I disorder manic episodes (1.2) • Bipolar disorder, depressive episodes (1.2) 1.1 Schizophrenia SEROQUEL is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13-17 years). The effectiveness of SEROQUEL for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.1) ]. 1.2 Bipolar Disorder SEROQUEL is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10-17 years) [see Clinical Studies (14.2) ]. SEROQUEL is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [see Clinical Studies (14.2) ]. SEROQUEL is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of SEROQUEL as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2) ]. 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis...

Mechanism: The mechanism of action of quetiapine in the listed indications is unclear. However, the efficacy of quetiapine in these indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism. The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D 2 , but greater activity at 5HT 2A receptors, than the parent drug (quetiapine).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • SEROQUEL · QUETIAPINE FUMARATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
  • SEROQUEL · QUETIAPINE FUMARATE EQ 300MG BASE · TABLET, ORAL · Prescription · TE AB
  • SEROQUEL · QUETIAPINE FUMARATE EQ 200MG BASE · TABLET, ORAL · Prescription · TE AB
  • SEROQUEL · QUETIAPINE FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB
  • SEROQUEL · QUETIAPINE FUMARATE EQ 400MG BASE · TABLET, ORAL · Prescription · TE AB
  • SEROQUEL · QUETIAPINE FUMARATE EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • SEROQUEL · QUETIAPINE FUMARATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Quetiapine" as an intervention, any sponsor and status, largest first.

All 398 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,492
  • off label use9,102
  • toxicity to various agents8,281
  • diabetes mellitus7,992
  • insomnia7,269
  • somnolence6,823
  • drug interaction6,691
  • fatigue6,643
  • nausea6,296
  • anxiety6,218
  • weight increased6,164
  • depression5,996

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,549
20051,921
20063,134
20075,526
20083,245
20097,250
20107,817
20118,248
20128,422
20134,100
20145,067
20156,662
20166,646
20178,242
20189,649
20199,933
202010,079
20219,051
20228,575
20238,805
20248,863
20258,363
20266,339

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Seroquel (Quetiapine Fumarate)

2024 spending

$8.7M

Beneficiaries

1,904

11,938 claims

Per beneficiary

$4,568

$10.28 per unit

View as table
YearSpending
2020$12,952,261
2021$11,504,475
2022$10,635,009
2023$9,868,368
2024$8,697,238

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,194 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.